Abstract
BackgroundHigh serum interleukin (IL-6) levels may cause resistance to immunotherapy by modulation of myeloid cells in the tumor microenvironment. IL-6 signaling blockade is tested in cancer, but as this inflammatory...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have